Anti-Inflammatory Effect of Simvastatin in Hemodialysis Patients

Jundishapur Journal of Natural Pharmaceutical Products

Volumn 10, Issue 1, 2015, Pages

  Shahbazian, Heshmatollah ^a   Atrian, Afagh ^a   Yazdanpanah, Leila ^a   Lashkarara, Gholam Reza ^a   Mohtashami, Azita Zafar ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anti inflammatory Agents; Renal Dialysis; Simvastatin

Indexed keywords

EID: 84948711148     PISSN: 17357780     EISSN: 22287876     Source Type: Journal    
DOI: 10.17795/jjnpp-17962     Document Type: Article

References (12)

1. van den Akker JM, Bredie SJ, Diepenveen SH, van Tits LJ, Stalenhoef AF, van Leusen R. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol. 2003;16(2):238–44.
2. Navarro JF, Mora C, Muros M, Garcia-Idoate G. Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis. Nephron Clin Pract. 2003;95(4):c128–35.
3. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G, Cholesterol., et al. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int. 2005;68(1):237–45.
4. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis. 2002;39(6):1213–7.
5. Holmberg B, Brannstrom M, Bucht B, Crougneau V, Dimeny E, Ekspong A, et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scand J Urol Nephrol. 2005;39(6):503–10.
6. Endres M. Statins: potential new indications in inflammatory conditions. Atheroscler Suppl. 2006;7(1):31–5.
7. D'Amico G. Statins and renal diseases: from primary prevention to renal replacement therapy. J Am Soc Nephrol. 2006;17(4 Suppl 2):S148–52.
8. Sirken G, Cheng KS, Rasib R. Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy. ASAIOJ. 2003;49:422–5.
9. Vernaglione L, Cristofano C, Muscogiuri P, Chimienti S. Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Am J Kidney Dis. 2004;43(3):471–8.
10. Panichi V, Paoletti S, Mantuano E, Manca-Rizza G, Filippi C, Santi S, et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol Dial Transplant. 2006;21(2):337–44.
11. Tsirpanlis G, Boufidou F, Manganas S, Chantzis K, Bleta A, Stamatelou K, et al. Treatment with fluvastatin rapidly modulates, via different pathways, and in dependence on the baseline level, inflammation in hemodialysis patients. Blood Purif. 2004;22(6):518–24.
12. Judith M. Atorvastatin and Simvastatin in patients on hemodialysis. J Nephrol. 2003;16(2):238–44.